Anne-Lise Børresen-Dale

Anne-Lise Børresen-Dale's AcademicInfluence.com Rankings

Philosophy

#3809

World Rank

#6095

Historical Rank

Logic

#1757

World Rank

#2594

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Anne-Lise Børresen-Dale Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Anne-Lise Børresen-Dale is a Norwegian biochemist. She is a senior scientist at Oslo University Hospital and Professor of molecular tumor biology at the University of Oslo. She received the 2002 Nordic Medical Prize. In 2015 she received the Fritjof Nansen medal and award for Outstanding Research from the Norwegian Academy of Science and Letters, and in 2017 she was appointed to Commander of the Royal Norwegian St. Olavs Order by the King of Norway.

(See a Problem?)

Anne-Lise Børresen-Dale's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Molecular portraits of human breast tumours (2000) (14829)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications (2001) (10949)
Signatures of mutational processes in human cancer (2013) (7589)
Repeated observation of breast tumor subtypes in independent gene expression data sets (2003) (5412)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups (2012) (4591)
International network of cancer genome projects (2010) (1839)
Mutational Processes Molding the Genomes of 21 Breast Cancers (2012) (1622)
The landscape of cancer genes and mutational processes in breast cancer (2012) (1610)
Landscape of somatic mutations in 560 breast cancer whole genome sequences (2016) (1574)
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors (2002) (1200)
The Life History of 21 Breast Cancers (2012) (1180)
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes (2016) (1125)
Extensive and coordinated transcription of noncoding RNAs within cell cycle promoters (2011) (1066)
Allele-specific copy number analysis of tumors (2010) (934)
Association analysis identifies 65 new breast cancer risk loci (2017) (922)
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes (2007) (834)
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients (1996) (763)
Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway (2012) (728)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures (2017) (644)
Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers (2006) (628)
Genome-wide analysis of DNA copy number variation in breast cancer using DNA microarrays (1999) (601)
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes (2018) (559)
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer (2006) (527)
Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants (2015) (471)
Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. (2004) (432)
Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms (2006) (408)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. (1992) (373)
RAD51B in Familial Breast Cancer (2016) (366)
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer (2014) (358)
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. (2001) (348)
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome (2008) (346)
Principles and methods of integrative genomic analyses in cancer (2014) (343)
TP53 and breast cancer (2003) (339)
Gene expression patterns in ovarian carcinomas. (2003) (333)
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. (2020) (322)
Novel patterns of genome rearrangement and their association with survival in breast cancer. (2006) (322)
miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors (2011) (311)
Identification of fusion genes in breast cancer by paired-end RNA-sequencing (2011) (308)
Large-scale genomic analyses link reproductive ageing to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair (2015) (308)
Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes (2014) (289)
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer (2007) (288)
Mutation of GATA3 in human breast tumors (2004) (279)
Triple‐negative breast cancer: Present challenges and new perspectives (2010) (265)
Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. (1995) (254)
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer (2017) (244)
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. (2014) (243)
Insight into the heterogeneity of breast cancer through next-generation sequencing. (2011) (235)
Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines (2009) (233)
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation (2012) (230)
TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance (2014) (228)
SERUM-HIGH-DENSITY-LIPOPROTEIN AND ATHEROSCLEROTIC HEART-DISEASE (1976) (226)
Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. (2001) (224)
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers (2010) (224)
RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. (2005) (216)
Systems biology and genomics of breast cancer. (2011) (211)
TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains (1995) (206)
Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent (2016) (205)
Somatic mutations reveal asymmetric cellular dynamics in the early human embryo (2017) (204)
Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. (1994) (199)
Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. (1991) (198)
The topography of mutational processes in breast cancer genomes (2016) (198)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Screening for germ line TP53 mutations in breast cancer patients. (1992) (196)
Different genetic pathways to proximal and distal colorectal cancer influenced by sex‐related factors (1997) (195)
Human CYP1A1 (cytochrome P(1)450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. (1991) (193)
Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. (2011) (192)
Prognostic significance of TP53 alterations in breast carcinoma. (1993) (188)
Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers (2011) (187)
A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients (2014) (180)
Somatic mutations in the hMSH2 gene in microsatellite unstable colorectal carcinomas. (1995) (179)
E‐cadherin and α‐, β‐, and γ‐catenin protein expression in relation to metastasis in human breast carcinoma (1998) (178)
Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters. (2017) (176)
Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer (2004) (174)
The Life History of 21 Breast Cancers (2015) (173)
CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. (1999) (168)
p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation (2008) (165)
CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. (2012) (164)
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling (2011) (162)
Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer (2010) (161)
Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis (2014) (160)
Genomic Architecture Characterizes Tumor Progression Paths and Fate in Breast Cancer Patients (2010) (160)
Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression (2010) (159)
High‐throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth (2014) (158)
CGH-Explorer: a program for analysis of array-CGH data (2005) (157)
Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations. (1998) (157)
Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility (1994) (153)
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. (2003) (153)
Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer (2007) (153)
Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling (2013) (148)
p53 abnormalities in different subtypes of human sarcomas. (1993) (145)
Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis (2002) (145)
TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. (1998) (142)
Discovery and validation of breast cancer subtypes (2006) (140)
Triple-negative breast cancer and the need for new therapeutic targets. (2013) (137)
Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer (2006) (136)
DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response (2010) (132)
p53 polymorphism and risk of cervical cancer (1998) (131)
Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer (2009) (129)
Gene expression profiling of peripheral blood cells for early detection of breast cancer (2010) (128)
The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. (2002) (128)
Familial testicular cancer in Norway and southern Sweden. (1996) (128)
Breast cancer and other cancers in Norwegian families with ataxia‐telangiectasia (1990) (127)
Breast cancer quantitative proteome and proteogenomic landscape (2019) (127)
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer (2010) (126)
Early detection of breast cancer based on gene-expression patterns in peripheral blood cells (2005) (126)
DNA methylation patterns in luminal breast cancers differ from non‐luminal subtypes and can identify relapse risk independent of other clinical variables (2011) (124)
Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. (2010) (124)
A rare CYP19 (aromatase) variant may increase the risk of breast cancer. (1998) (124)
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 (2016) (122)
Study design: Evaluating gene–environment interactions in the etiology of breast cancer – the WECARE study (2004) (122)
Methylation profiling with a panel of cancer related genes: Association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer (2011) (120)
PIK3CA mutations in advanced ovarian carcinomas (2005) (120)
Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC. (2014) (119)
Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. (2014) (117)
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. (2012) (115)
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells (2015) (114)
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival (2011) (114)
Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. (1996) (114)
Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer (2013) (113)
EGF Decreases the Abundance of MicroRNAs That Restrain Oncogenic Transcription Factors (2010) (112)
Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2014) (112)
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models (2010) (111)
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. (2011) (111)
Molecular profiling and characterization of luminal‐like and basal‐like in vivo breast cancer xenograft models (2009) (110)
Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study (2010) (109)
Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas (1992) (109)
Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. (2013) (109)
Genetic variants of CYP19 (aromatase) and breast cancer risk (2000) (108)
Merging transcriptomics and metabolomics - advances in breast cancer profiling (2010) (108)
Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes (2016) (108)
Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c (2014) (108)
p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. (1994) (108)
Common Breast Cancer Susceptibility Variants in LSP1 and RAD51L1 Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk (2012) (107)
Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity (2012) (104)
Deletion of 1p loci and microsatellite instability in colorectal polyps (1995) (103)
Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival (2001) (103)
Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations. (1994) (102)
Loss of 3p or 11p alleles is associated with testicular cancer tumors. (1989) (102)
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer (2011) (99)
DNA methylation at enhancers identifies distinct breast cancer lineages (2017) (97)
Association of ESR1 gene tagging SNPs with breast cancer risk. (2009) (95)
Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients. (1998) (95)
Second non-germ cell malignancies after radiotherapy of testicular cancer with or without chemotherapy. (1990) (94)
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment (2019) (94)
Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. (1992) (93)
A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients (2008) (93)
Genome‐wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients (2008) (91)
Re-expression of E-cadherin, alpha-catenin and beta-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [seecomments]. (2000) (91)
Alternative splicing and mutation status of CHEK2 in stage III breast cancer (2004) (89)
Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. (1998) (89)
TP53 Mutations in Breast and Ovarian Cancer. (2017) (89)
Lp(a) phenotypes, other lipoprotein parameters, and a family history of coronary heart disease in middle‐aged males (1979) (89)
ATM Is Not Required in Somatic Hypermutation of VH, but Is Involved in the Introduction of Mutations in the Switch μ Region1 (2003) (88)
Processed pseudogenes acquired somatically during cancer development (2014) (87)
Microarray analysis of the transcriptional response to single or multiple doses of ionizing radiation in human subcutaneous fibroblasts. (2005) (87)
Genetic variants of CYP19 (aromatase) and breast cancer risk (2000) (86)
Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration (2016) (86)
Features of 5'-splice-site efficiency derived from disease-causing mutations and comparative genomics. (2007) (85)
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome (2017) (85)
Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors (2013) (85)
Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. (1995) (83)
Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. (2008) (82)
Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. (1996) (82)
High frequency of skewed X inactivation in young breast cancer patients (2002) (81)
Alpha fetoprotein is increasing with age in ataxia-telangiectasia. (2007) (80)
Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. (2016) (80)
ESR1 gene amplification in breast cancer: a common phenomenon? (2008) (80)
Genetic alterations of the TP53 gene, p53 protein expression and hpv infection in primary cervical carcinomas (1993) (80)
Ki-ras mutations and prognosis in colorectal cancer. (1998) (79)
Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort (2014) (78)
Flt3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. (2007) (78)
Microsatellite instability in cervical and endometrial carcinomas (1997) (76)
E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. (1998) (76)
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. (2016) (76)
Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells (2015) (75)
Different genetic components in the Norwegian population revealed by the analysis of mtDNA and Y chromosome polymorphisms (2002) (74)
LIMT is a novel metastasis inhibiting lncRNA suppressed by EGF and downregulated in aggressive breast cancer (2016) (73)
Localization of an ataxia-telangiectasia gene to an approximately 500-kb interval on chromosome 11q23.1: linkage analysis of 176 families by an international consortium. (1995) (72)
Loss of heterozygosity at 11q23.1 in breast carcinomas: Indication for involvement of a gene distal and close to ATM (1997) (72)
Alterations of p53 and expression of WAF1/p21 in human thyroid tumors. (1996) (71)
The Genetics and Epigenetics of Fatigue (2010) (71)
The circular RNome of primary breast cancer (2019) (70)
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells (2013) (70)
Focal amplification and oncogene dependency of GAB2 in breast cancer (2010) (70)
Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors (2013) (69)
BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations (2010) (69)
Comparison of the Agilent, ROMA/NimbleGen and Illumina platforms for classification of copy number alterations in human breast tumors (2008) (69)
Genetic modifiers of CHEK2*1100delC associated breast cancer risk (2016) (68)
TP53 allele loss, mutations and expression in malignant melanoma. (1994) (67)
BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. (2017) (67)
A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers (2017) (67)
Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency. (2017) (67)
Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors (2017) (67)
Intratumor heterogeneity defines treatment‐resistant HER2+ breast tumors (2018) (66)
Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. (1990) (66)
An increased risk of cervical intra‐epithelial neoplasia grade II‐III among human papillomavirus positive patients with the HLA‐DQA1*0102‐DQB1*0602 haplotype: A population‐based case–control study of Norwegian women (1998) (66)
Genetic alterations within the retinoblastoma locus in colorectal carcinomas. Relation to DNA ploidy pattern studied by flow cytometric analysis. (1991) (65)
GSTM1 and NAT2 polymorphisms in operable and non-operable lung cancer patients. (2000) (65)
Genomics in breast cancer—therapeutic implications (2005) (65)
Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing (2016) (65)
TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival (2004) (65)
TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients (2016) (64)
No germline TP53 mutations detected in familial and bilateral testicular cancer (1993) (64)
Deciphering Normal Blood Gene Expression Variation—The NOWAC Postgenome Study (2010) (64)
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation (2016) (63)
Genome‐wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis (2015) (63)
Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins (2013) (63)
Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer (2007) (62)
Designing and implementing quality control for multi‐center screening of mutations in the ATM gene among women with breast cancer (2003) (62)
Chromosome region 8p11‐p21: Refined mapping and molecular alterations in breast cancer (1998) (62)
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma (2004) (61)
Disease-specific genomic analysis: identifying the signature of pathologic biology (2007) (60)
Estrogen Receptor Beta (ESR2) Polymorphisms in Familial and Sporadic Breast Cancer (2005) (60)
Gene expression analyses in breast cancer epidemiology: the Norwegian Women and Cancer postgenome cohort study (2008) (60)
Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) (2012) (60)
Cohort profile: the Gateshead Millennium Study. (2011) (59)
Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures. (2015) (59)
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus (2016) (58)
P53 mutations in gastric carcinomas. (1992) (58)
CAMK1D amplification implicated in epithelial–mesenchymal transition in basal‐like breast cancer (2008) (57)
Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas (2014) (57)
TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas (1997) (57)
Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. (2003) (56)
Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes (2016) (56)
Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. (2005) (54)
The gene for apolipoprotein C‐ll is closely linked to the gene for apolipoprotein E on chromosome 19 (1984) (53)
Molecular genetic changes in human male germ cell tumors. (1995) (53)
Subtype‐specific micro‐RNA expression signatures in breast cancer progression (2016) (53)
GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. (2008) (53)
Profiling of microRNAs in tumor interstitial fluid of breast tumors – a novel resource to identify biomarkers for prognostic classification and detection of cancer (2016) (52)
High‐resolution analyses of copy number changes in disseminated tumor cells of patients with breast cancer (2012) (52)
Molecular heterogeneity in the mild autosomal dominant forms of osteogenesis imperfecta. (1984) (52)
Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors. (1992) (52)
c-erbB-2 expression in primary gastric carcinomas and their metastases. (1992) (51)
Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia (2005) (50)
Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2 (2015) (50)
Erratum: The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes (2016) (50)
Papillomaviruses, p53, and cervical cancer (1992) (50)
DNA Methylation Status of Key Cell-Cycle Regulators Such as CDKNA2/p16 and CCNA1 Correlates with Treatment Response to Doxorubicin and 5-Fluorouracil in Locally Advanced Breast Tumors (2014) (49)
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. (1998) (49)
Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction. (1998) (48)
Identifying In-Trans Process Associated Genes in Breast Cancer by Integrated Analysis of Copy Number and Expression Data (2013) (48)
Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes (2007) (48)
Glycan‐related gene expression signatures in breast cancer subtypes; relation to survival (2015) (48)
Alterations of gene expression in blood cells associated with chronic fatigue in breast cancer survivors (2009) (47)
Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53 (2014) (47)
Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk (2014) (47)
Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density (2010) (47)
NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations (2010) (47)
ATM variants 7271T>G and IVS10-6T>G among women with unilateral and bilateral breast cancer (2003) (47)
Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics (2016) (47)
DQA1 and DQB1 genes in patients with squamous cell carcinoma of the cervix: relationship to human papillomavirus infection and prognosis. (1994) (46)
The TP53 tumour suppressor gene in colorectal carcinomas. II. Relation to DNA ploidy pattern and clinicopathological variables. (1993) (46)
Lysophosphatidic Acid-Induced Transcriptional Profile Represents Serous Epithelial Ovarian Carcinoma and Worsened Prognosis (2009) (46)
Apparent influence of marker genotypes on variation in serum cholesterol in monozygotic twins (1981) (46)
Low frequency of E-cadherin alterations in familial breast cancer (2001) (46)
The importance of gene-centring microarray data. (2010) (46)
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts (2014) (46)
Genetic predisposition to ductal carcinoma in situ of the breast (2016) (46)
Microarrays in primary breast cancer--lessons from chemotherapy studies. (2001) (45)
Genome-wide association study of germline variants and breast cancer-specific mortality (2019) (44)
Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. (2008) (44)
Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer (2003) (44)
Germline glutathione S-transferase variants in breast cancer: relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy. (2007) (44)
SNP in TXNRD2 associated with radiation-induced fibrosis: a study of genetic variation in reactive oxygen species metabolism and signaling. (2013) (43)
Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. (2014) (43)
Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection. (1995) (43)
Detection of base mutations in genomic DNA using denaturing gradient gel electrophoresis (DGGE) followed by transfer and hybridization with gene-specific probes. (1988) (43)
MicroRNA‐135b regulates ERα, AR and HIF1AN and affects breast and prostate cancer cell growth (2015) (42)
Identical mutation in 55% of the ATM alleles in 11 Norwegian AT families: evidence for a founder effect (1998) (42)
Combining Gene Signatures Improves Prediction of Breast Cancer Survival (2011) (42)
Epithelial-stromal interaction 1 (EPSTI1) substitutes for peritumoral fibroblasts in the tumor microenvironment. (2010) (42)
Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study (2008) (42)
Studies of the L-myc DNA polymorphism and relation to metastasis in Norwegian lung cancer patients. (1990) (41)
Sex differences in oncogenic mutational processes (2019) (41)
Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features (2011) (41)
Marfan syndrome: exclusion of genetic linkage to the COL1A2 gene. (1986) (41)
Genetic variation in putative regulatory loci controlling gene expression in breast cancer (2006) (41)
Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status (2014) (41)
Interaction between bcl‐2 and p21 (WAF1/CIP1) in breast carcinomas with wild‐type p53 (1997) (41)
A common BRCA1 mutation in Norwegian breast and ovarian cancer families? (1996) (41)
Presence of "free" apoA-I in serum: implications for immunological quantification of HDL and its apoproteins. (1980) (40)
Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence (2007) (40)
Risk of cancer in relatives of testicular cancer patients. (1996) (40)
A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. (2014) (40)
Linear and non-linear dependencies between copy number aberrations and mRNA expression reveal distinct molecular pathways in breast cancer (2011) (39)
The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen‐receptor positive tumors (2014) (39)
Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. (2015) (39)
Integrated analysis of high‐resolution DNA methylation profiles, gene expression, germline genotypes and clinical end points in breast cancer patients (2014) (39)
Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. (1997) (39)
Amplified Loci on Chromosomes 8 and 17 Predict Early Relapse in ER-Positive Breast Cancers (2012) (39)
When do mothers think their child is overweight? (2010) (39)
A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer (2014) (38)
11q13 is a susceptibility locus for hormone receptor positive breast cancer (2012) (38)
Fine‐scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer (2016) (38)
High prevalence of germline STK11 mutations in Hungarian Peutz-Jeghers Syndrome patients (2010) (38)
Analyzing cancer samples with SNP arrays. (2012) (38)
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer (2019) (38)
Identification of genetic variation in 11 candidate genes of canine mammary tumour. (2011) (37)
Breast cancer information on the web (1995) (37)
Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation (2018) (37)
Frequent loss of 11p13 and 11p15 loci in male germ cell tumours (1993) (37)
Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas (2011) (36)
A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide (2009) (36)
Direct Transcriptional Consequences of Somatic Mutation in Breast Cancer (2016) (36)
Long Non-Coding RNAs Differentially Expressed between Normal versus Primary Breast Tumor Tissues Disclose Converse Changes to Breast Cancer-Related Protein-Coding Genes (2014) (35)
Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. (1994) (35)
Influence of TP 53 Gene Alterations and c-erbB2 Expression on the Response to Treatment with Doxorubicin in Locally Advanced Breast Cancer 1 (2001) (35)
Candidate locus analysis of the TERT–CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk (2014) (34)
Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications. (2005) (34)
TP53 alterations in relation to the cell cycle‐associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus (1999) (34)
ABCB1 and GST polymorphisms associated with TP53 status in breast cancer (2007) (34)
Expression of E-cadherin and its relation to the p53 protein status in human breast carcinomas (1997) (34)
Mutations in exons 5–8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma (1999) (33)
Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load. (1998) (33)
Next-Generation Sequencing of Disseminated Tumor Cells (2013) (33)
Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21 (2016) (33)
ATM variants and cancer risk in breast cancer patients from Southern Finland (2006) (33)
Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer (2015) (33)
Loss of heterozygosity at 11q23.1 and survival in breast cancer: Results of a large European study (1999) (33)
Screening for ESR mutations in breast and ovarian cancer patients (1997) (32)
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (32)
No germline TP53 mutations detected in familial and bilateral testicular cancer. (1993) (32)
Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas. (2005) (32)
Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers (2010) (32)
The TP53 tumour suppressor gene in colorectal carcinomas. I. Genetic alterations on chromosome 17. (1993) (32)
Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study (2014) (31)
Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution (2009) (31)
Serum N‐glycan analysis in breast cancer patients – Relation to tumour biology and clinical outcome (2016) (31)
Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study (2014) (31)
Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas (2007) (31)
The effect of Gemfibrozil on human serum apolipoproteins and on serum reserve cholesterol binding capacity (SRCBC). (1981) (31)
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients (2005) (30)
Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection. (1991) (30)
Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in b‐cell non‐Hodgkin's lymphoma (2000) (29)
Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas (2015) (29)
Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue (2017) (29)
Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma (2017) (29)
Genetic alterations in a malignant schwannoma from a patient with neurofibromatosis (NF1). (1993) (29)
Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy (2014) (28)
Expression array technology in the diagnosis and treatment of breast cancer. (2002) (28)
Ischemia caused by time to freezing induces systematic microRNA and mRNA responses in cancer tissue (2011) (28)
High‐resolution gene copy number and expression profiling of human chromosome 22 in ovarian carcinomas (2005) (28)
Constant Denaturant Gel Electrophoresis (CDGE) in Mutation Screening (1996) (28)
Expression of full-length p53 and its isoform Δp53 in breast carcinomas in relation to mutation status and clinical parameters (2006) (28)
K-ras oncogene codon 12 point mutations in testicular cancer. (1993) (28)
The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma. (2016) (28)
In Silico Ascription of Gene Expression Differences to Tumor and Stromal Cells in a Model to Study Impact on Breast Cancer Outcome (2010) (28)
Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis. (2005) (28)
Canine Mammary Tumours Are Affected by Frequent Copy Number Aberrations, including Amplification of MYC and Loss of PTEN (2015) (27)
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis (2020) (27)
The molecular weight of sodium hyaluronate in amniotic fluid. (1986) (27)
The APC gene I1307K variant is rare in Norwegian patients with familial and sporadic colorectal or breast cancer. (1998) (27)
Oncogenesis in ovarian cancer (1992) (27)
A supervised approach for identifying discriminating genotype patterns and its application to breast cancer data (2007) (26)
Truncating somatic mutation in exon 15 of the APC gene is a rare event in human breast carcinomas. Mutations in brief no. 179. Online. (1998) (26)
Framework for Identifying Common Aberrations in DNA Copy Number Data (2007) (26)
Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study (2010) (26)
Contribution of APC and MUTYH mutations to familial adenomatous polyposis susceptibility in Hungary (2015) (25)
miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth. (2019) (25)
Radiation-induced effects on gene expression: an in vivo study on breast cancer. (2006) (25)
Pathway based analysis of SNPs with relevance to 5‐FU therapy: Relation to intratumoral mRNA expression and survival (2008) (25)
Expression of cyclin Ds in relation to p53 status in human breast carcinomas (1998) (25)
Detection of low-frequency mutations in exon 8 of the TP53 gene by constant denaturant capillary electrophoresis (CDCE). (1999) (25)
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer (2017) (25)
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53 (2013) (25)
Genome-wide DNA methylation profiles in progression to in situand invasive carcinoma of the breast with impact on gene transcription and prognosis (2014) (25)
Subtype‐specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts (2013) (24)
Prognostic and Predictive Value of TP53 Mutations in Human Cancer (2007) (24)
Prenatal diagnosis of hereditary tyrosinemia by determination of fumarylacetoacetase in cultured amniotic fluid cells. (1985) (24)
Metachromatic leukodystrophy: (1973) (24)
Basal‐like breast cancer engages tumor‐supportive macrophages via secreted factors induced by extracellular S100A4 (2018) (24)
Global Gene Expression Analysis Reveals a Link between NDRG1 and Vesicle Transport (2014) (23)
Signatures of mutational processes in human cancer this access benefits you. Your matters (2013) (23)
High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival (2013) (23)
Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics (2018) (22)
Common Genetic Variation in GATA-Binding Protein 3 and Differential Susceptibility to Breast Cancer by Estrogen Receptor α Tumor Status (2007) (22)
Excess of miRNA-378a-5p perturbs mitotic fidelity and correlates with breast cancer tumourigenesis in vivo (2014) (22)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer (2019) (22)
Interactions between the tumor and the blood systemic response of breast cancer patients (2017) (22)
Breast cancer risk variants at 6 q 25 display different phenotype associations and regulate ESR 1 , RMND 1 and CCDC 170 (2016) (22)
The expression of the long NEAT1_2 isoform is associated with human epidermal growth factor receptor 2-positive breast cancers (2020) (21)
Serum N‐glycome alterations in breast cancer during multimodal treatment and follow‐up (2017) (21)
Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within the FHIT gene: Evaluation of allelic imbalance at FHIT, RB1 and TP53 in relation to survival (2000) (21)
TP53 alterations in atypical ductal hyperplasia and ductal carcinomain situ of the breast (2005) (21)
N‐glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome (2018) (21)
Effect of haptoglobin subtypes on serum lipid levels. (1987) (21)
ATM mutations in Finnish breast cancer patients (2002) (20)
Multiplex single-tube screening for mutations in the Nijmegen Breakage Syndrome (NBS1) gene in Hodgkin's and non-Hodgkin's lymphoma patients of Slavic origin (2003) (20)
C-erbB-2 protein and neuroendocrine expression in breast carcinomas. (1991) (20)
Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer (1997) (20)
Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF (2015) (20)
Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas (2015) (20)
Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry (2016) (20)
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy (2015) (20)
No association between radiosensitivity and TP53 status, G1 arrest or protein levels of p53, myc, ras or raf in human melanoma lines. (1999) (20)
2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy (2014) (19)
Automated constant denaturant capillary electrophoresis applied for detection of KRAS exon 1 mutations. (2001) (19)
Mutation screening of BRCA1 using PTT and LOH analysis at 17q21 in breast carcinomas from familial and non-familial cases (1998) (19)
Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation (2009) (18)
Genome-wide association study in breast cancer survivors reveals SNPs associated with gene expression of genes belonging to MHC class I and II. (2013) (18)
European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables (1999) (18)
HIGH DENSITY LIPOPROTEIN (HDL) POLYMORPHISMS IN RABBIT I. A COMPARATIVE STUDY OF RABBIT AND HUMAN SERUM HIGH DENSITY LIPOPROTEIN (1976) (18)
Mutant p 53 cooperates with the SWI / SNF chromatin remodeling complex to regulate VEGFR 2 in breast cancer cells (2015) (18)
Intragenic reorganization of RB1 in a complex (4;13) rearrangement demonstrated by FISH. (1994) (18)
Mutations and polymorphisms of the p21B transcript in breast cancer (2007) (18)
Screening for mutations in human HPRT cDNA using the polymerase chain reaction (PCR) in combination with constant denaturant gel electrophoresis (CDGE). (1992) (17)
The multitude of molecular analyses in cancer: the opening of Pandora’s box (2014) (17)
Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy (2017) (17)
Gene expression profiling of whole-blood samples from women exposed to hormone replacement therapy (2006) (17)
TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival (2005) (17)
MicroRNA let‐7b regulates genomic balance by targeting Aurora B kinase (2015) (17)
Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer (2005) (17)
p53 alterations in gastric carcinoma: a study of 56 primary tumors and 204 nodal metastases. (1994) (17)
The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer (2015) (17)
The Novel p21 Polymorphism p21G251A Is Associated with Locally Advanced Breast Cancer (2006) (17)
Common genetic variation in GATA-binding protein 3 and differential susceptibility to breast cancer by estrogen receptor alpha tumor status. (2007) (16)
The c-erbB-2 protein in primary and metastatic breast carcinomas. (1991) (16)
Comparison of globin RNA processing methods for genome-wide transcriptome analysis from whole blood. (2008) (16)
Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab (2018) (16)
Rare Ha‐ras1 alleles and predisposition to testicular cancer (2009) (16)
Metachromatic leukodystrophy (1973) (16)
Transcriptional networks inferred from molecular signatures of breast cancer. (2008) (16)
DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival (2016) (16)
A systematic comparison of copy number alterations in four types of female cancer (2016) (16)
Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis. (1993) (16)
Association studies of estrogen receptor polymorphisms in a Norwegian testicular cancer population. (1995) (16)
Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma (2016) (16)
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations (2018) (16)
Genetic Haplotyping of Ataxia-telangiectasia Families Localizes the Major Gene to an ∼ 850 kb Region on Chromosome 11q23.1. (1994) (16)
Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. (1996) (15)
Paired distribution of molecular subtypes in bilateral breast carcinomas. (2011) (15)
On the proposed association of the ATM variants 5557G>A and IVS38‐8T>C and bilateral breast cancer (2006) (15)
A comparison of different modes for the detection of p53 protein accumulation. A study of bladder cancer. (1997) (15)
Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. (2017) (15)
Overrepresentation of transcription factor families in the genesets underlying breast cancer subtypes (2012) (15)
Blood gene expression profiling of breast cancer survivors experiencing fibrosis. (2011) (15)
BRCA1 mutation screening using restriction endonuclase fingerprinting‐single‐strand conformation polymorphism in an automated capillary electrophoresis system (2002) (15)
Genome scanning of human breast carcinomas using micro- and minisatellite core probes. (1993) (15)
SERUM-H.D.L. IN ATHEROSCLEROTIC HEART-DISEASE (1976) (15)
Role of genetic factors in breast cancer susceptibility. (1992) (15)
Genetic modifiers of CHEK 2 * 1100 delC-associated breast cancer risk (2017) (15)
Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening (1998) (14)
Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases. (2017) (14)
Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus (2016) (14)
X chromosome inactivation in cervical cancer patients. (2003) (14)
Deficiency of fumarylacetoacetase without hereditary tyrosinemia (1985) (14)
Effect of gemfibrozil on serum lipid levels. (1980) (14)
Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions (2020) (14)
Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity (2017) (14)
Multilocus analysis of SNP and metabolic data within a given pathway (2006) (13)
A TP53 mutation detected in cells established from an osteosarcoma, but not in the retinoblastoma of a patient with bilateral retinoblastoma and multiple primary osteosarcomas. (1992) (13)
Corrigendum: Signatures of mutational processes in human cancer (2013) (13)
Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer. (2015) (13)
Analysis of SNP-expression association matrices (2006) (13)
Detection of ras gene mutations in human lung cancer: comparison of two screening assays based on the polymerase chain reaction. (1992) (13)
Found in transcription: gene expression and other novel blood biomarkers for the early detection of breast cancer (2009) (13)
PRENATAL DIAGNOSIS OF HOMOCYSTINURIA (1982) (13)
ATM variants 7271 T 4 G and IVS 10-6 T 4 G among women with unilateral and bilateral breast cancer (2003) (12)
Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer (2021) (12)
Detection of mutations by single-strand conformation polymorphism (SSCP) analysis and SSCP-hybrid methods. (2001) (12)
International Agency for Research on Cancer Workshop on 'Expression array analyses in breast cancer taxonomy' (2006) (12)
TP53 gene mutations and protein accumulation in primary vaginal carcinomas. (1995) (12)
implications Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical (2001) (12)
AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth (2017) (12)
Allelic imbalance at chromosome region 11q23 in cervical carcinomas. (1999) (12)
Genetic alterations of chromosome 17 in human breast carcinoma studied by fluorescence in situ hybridization and molecular DNA techniques. (1994) (12)
Chromosome 12 in human testicular cancer: dosage changes and their parental origin. (1992) (12)
SNPs associated with molecular subtypes of breast cancer: On the usefulness of stratified Genome‐wide Association Studies (GWAS) in the identification of novel susceptibility loci (2008) (12)
PURIFICATION AND PARTIAL CHARACTERIZATION OF THE apoA‐I OF RABBIT HIGH DENSITY LIPOPROTEIN (1978) (11)
BRCA1 screening in patients with a family history of breast or ovarian cancer. (1999) (11)
Fibroblast Growth Factor Receptor 3 (FGFR3)–Analyses of the S249C Mutation and Protein Expression in Primary Cervical Carcinomas (2001) (11)
BUB1 infrequently mutated in human breast carcinomas (2003) (11)
HIGH DENSITY LIPOPROTEIN (HDL) POLYMORPHISMS IN RABBIT II. A STUDY OF THE INHERITED HI 1 AND R 67 ANTIGENS IN RELATION TO HDL POLYPEPTIDES (1976) (11)
On the molecular biology of breast cancer (2010) (10)
Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium (2015) (10)
No alterations in exon 21 of the RBI gene in sarcomas and carcinomas of the breast, colon, and lung (1992) (10)
A retroviral vector for siRNA expression in mammalian cells (2007) (10)
Acute myelogenous leukemia in a patient with Li–Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report (2006) (10)
Genetic haplotyping of ataxia-telangiectasia families localizes the major gene to an approximately 850 kb region on chromosome 11q23.1. (1994) (10)
Discovery and validation of breast cancer subtypes (2007) (10)
Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer (2011) (10)
High‐throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype‐specific serologically relevant biomarkers (2020) (10)
Nuclear CSPP1 expression defined subtypes of basal-like breast cancer (2014) (10)
A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients (2015) (10)
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER‐positive breast cancer (2020) (10)
The TP 53 Codon 72 Polymorphism May Affect the Function of TP 53 Mutations in Breast Carcinomas but not in Colorectal Carcinomas 1 (2002) (10)
Flt 3 Y 591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p 53 (2006) (10)
Detection of DNA variation in cancer. (1992) (10)
Management considerations for subtidal Zostera marina beds in Ireland (2007) (10)
Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: Possible role of host factors and survival bias (2007) (10)
Quantitative Multigene FISH on Breast Carcinomas Identifies der(1;16)(q10;p10) as an Early Event in Luminal A Tumors (2014) (10)
Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences (2019) (10)
Screening of 229 family cancer patients for a germline estrogen receptor gene (ESR) base mutation (1997) (9)
Allele diversity of the H-ras-1 variable number of tandem repeats in Norwegian lung cancer patients. (1992) (9)
TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients. (2007) (9)
Detection of Mutations by Denaturing Gradient Gel Electrophoresis (1998) (9)
Association between apolipoprotein E genotypes and cancer risk in patients with acquired immunodeficiency syndrome. (2000) (9)
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate (2017) (9)
Experimental validation of data mined single nucleotide polymorphisms from several databases and consecutive dbSNP builds (2006) (9)
Lymphocyte Invasion in IC 10 / Basal-Like Breast Tumors Is Associated with Wild-Type TP 53 (2015) (9)
HIGH DENSITY LIPOPROTEIN (HDL) POLYMORPHISMS IN RABBIT III. QUANTITATIVE DETERMINATION OF HDL AND THE INHERITED H1 1 AND R 67 ANTIGENS (1976) (8)
PstI polymorphism at the human P1450 gene on chromosome 15. (1990) (8)
Evaluation of MetriGenix custom 4D™ arrays applied for detection of breast cancer subtypes (2006) (8)
DNA copy number motifs are strong and independent predictors of survival in breast cancer (2020) (8)
Screening breast cancer patients for Norwegian ATM mutations (2000) (8)
Low density lipoprotein receptor activity in cultured fibroblasts from subjects with or without ischemic heart disease (in the absence of familial hypercholesterolemia) * (1981) (8)
Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer (2013) (8)
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer – the MetAction study (2020) (8)
Genetic profiling of breast cancer: from molecular portraits to clinical utility. (2003) (7)
Recurrent Fallopian Tube Carcinoma: TP53 Mutation and Clinical Course (2000) (7)
Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer (2020) (7)
A comparative study of serum amyloid a protein (SAA) from mink and man. (1984) (7)
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain (2019) (7)
Mismatch Detection Using Heteroduplex Analysis (2002) (7)
Abstract 2: Metabolomics analysis reveals distinct profiles of non-muscle invasive and muscle-invasive bladder cancer (2016) (7)
Common variants in breast cancer risk loci predispose to distinct tumor subtypes (2022) (6)
Serum reserve cholesterol binding capacity (SRCBC): the relative importance of different lipoprotein classes. (1981) (6)
Transcriptional response to ionizing radiation in human radiation sensitive cell lines. (2007) (6)
TP53 mutations in synchronous and metachronous bilateral breast carcinomas. (2008) (6)
Mutagenicity testing of human milk from smokers and non-smokers in the Salmonella/microsome test. (1987) (6)
Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. (2016) (6)
PIG SERUM HIGH DENSITY LIPOPROTEIN ANTIGEN REACTIVE WITH ANTISERA TO THE HL 1 RABBIT ALLOTYPE * (1975) (6)
398 Glycan gene expression signatures distinguish normal and malignant breast tissue; possible role in diagnosis and progression (2010) (6)
Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (2018) (6)
Common breast cancer risk loci predispose to distinct tumor subtypes (2019) (6)
Gene expression profiling of human dermal fibroblasts exposed to bleomycin sulphate does not differentiate between radiation sensitive and control patients (2011) (6)
THE DISTRIBUTION OF THE INHERITED Hl 1 AND R 67 ANTIGENS ON RABBIT SERUM HIGH DENSITY LIPOPROTEIN (HDL) PARTICLES (1978) (6)
Determinants of acquired activated protein C resistance and D-dimer in breast cancer. (2016) (6)
Towards personalized computer simulation of breast cancer treatment: a multi-scale pharmacokinetic and pharmacodynamic model informed by multi-type patient data (2018) (6)
Allele-specific disparity in breast cancer (2011) (5)
Title : BRCA 1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP 53 mutations (2010) (5)
Papillomaviruses, p53, and cervical cancer. (1992) (5)
Erratum: Constant denaturant gel electrophoresis, a modification of denaturing gradient gel electrophoresis, in mutation detection (Mutation Research, 262, 63-71 (1991)) (1991) (5)
Chromosome 13 alterations in osteosarcoma cell lines derived from a patient with previous retinoblastoma. (1991) (5)
Linkage disequilibrium analyses and restriction mapping of four RFLPs at the proα2(I) collagen locus: lack of correlation between linkage disequilibrium and physical distance (1988) (5)
Erratum: The Life History of 21 Breast Cancers (Cell 149 (994-1007)) (2015) (5)
Mutant Oncogenes. Targets for Therapy (1993) (5)
Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases (2017) (5)
Enhanced detection of mutations in BRCA1 exon 11 using restriction endonuclease fingerprinting-single-strand conformation polymorphism (2000) (5)
Workshop on The Epidemiology of the ATM Gene: Impact on Breast Cancer Risk and Treatment, Present Status and Future Focus, Lillehammer, Norway, 29 June 2002 (2002) (5)
Personalized Cancer Care Conference (2013) (4)
Candidate locus analysis of the TERT–CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk (2014) (4)
Genetic variation at CYP 3 A is associated with age at menarche and breast cancer risk : a case-control study (2014) (4)
[Microarray technology--potential in cancer research]. (2001) (4)
Gene Mutations Predict the Response to Neoadjuvant Treatment with 5-Fluorouracil and Mitomycin in Locally Advanced Breast Cancer (2003) (4)
p53 polymorphism and cervical cancer (1999) (4)
Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) (2012) (4)
[Early diagnosis of colorectal tumors]. (1995) (4)
Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors (2018) (4)
Transport and distribution of homocarnosine after intracerebroventricular and intravenous injection in the rat (1984) (4)
Contrasting DCIS and invasive breast cancer by subtype suggests basal-like DCIS as distinct lesions (2020) (4)
DNA polymorphisms in collagen genes: potential use in the study of disease. (1985) (4)
Ha-ras-1 alleles in Norwegian lung cancer patients (1990) (4)
Analysis of SNP-Expression Association Matrices (2005) (3)
Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin. (2005) (3)
Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy (2016) (3)
RFLPs in collagen loci and disease. (1986) (3)
Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk (2020) (3)
Partial purification and characterization of the inherited Hl 1 and R 67 antigens of rabbit serum high density lipoprotein. (1978) (3)
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers (2021) (3)
41 NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumours without TP53 mutations (2010) (3)
Hypervariable area in the 5′ flanking region of GSTP1, previously reported as a minisatellite ATAAA repeat (2001) (3)
Correction: miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors (2013) (3)
Serum Amyloid A Protein (SAA) from Mink, Horse, and Man: A Comparative Study (1986) (3)
Assessing TP53 status in human tumors: Lessons from breast cancer (2013) (2)
HIGH DENSITY LIPOPROTEIN (HDL) POLYMORPHISMS IN RABBIT: PRODUCTION OF ANTIBODY TO RABBIT ALLOTYPE (R 67) IN SHEEP (1977) (2)
Maximal low density lipoprotein receptor activity and the effect of lipid lowering diet on total serum cholesterol (1985) (2)
TP53 mutation and HPV-infection in primary cervical carcinomas (1992) (2)
Screening for base mutations in the PAH and HPRT loci using the polymerase chain reaction (PCR) in combination with denaturing gradient gel electrophoresis (DGGE). (1990) (2)
Genetic haplotyping of ataxia-telangiectasia families localizes the major gene to an ~850 kb region on chromosome 11 q23.1. (1994) (2)
Subtype and cell type specific expression of lncRNAs provide insight into breast cancer (2022) (2)
Molecular characteristics in breast cancer tumors treated with neoadjuvant chemotherapy with and without bevacizumab: Results from NeoAva— Randomized phase II study. (2015) (2)
PathTracer: High-sensitivity detection of differential pathway activity in tumours (2019) (2)
Tumour suppressor genes in breast cancer (1998) (2)
Correction to: A systematic comparison of copy number alterations in four types of female cancer (2018) (2)
Haplotypes associated to gene expression in breast cancer: can they lead us to the susceptibility markers? (2018) (2)
Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression (2021) (2)
Genetic Services in Norway (1997) (2)
Correction: Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: Relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patients (Pharmacogenetics, 8, 5 (441-447)) (1999) (2)
Abstract P2-10-20: A tumor DNA complexity index is an independent predictor of survival in a dataset of 1950 breast cancers; a METABRIC group study. (2012) (2)
Correction: TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance (2015) (2)
Screening breast cancer patients for Norwegian ATM mutations (2000) (2)
rs2735383, located at a microRNA binding site in the 3’UTR of NBS1, is not associated with breast cancer risk (2016) (2)
650 Use of the blood based, 96-assay set for breast cancer detection (2010) (2)
Cis-regulatory mutations associate with transcriptional and post-transcriptional deregulation of gene regulatory programs in cancers (2020) (2)
Expression profiling of peripheral blood cells for early detection (2005) (2)
Abstract A8: The EurOPDX consortium: Sharing patient tumor-derived xenografts for collaborative multicentric preclinical trials. (2013) (2)
Two truncating variants in FANCC and breast cancer risk (2019) (2)
648 Molecular characterization of breast cancer subtypes derived from joint analysis of high throughput miRNA and mRNA data (2010) (2)
Managing constipation and soiling. (2005) (2)
Tracking of fruit and vegetable consumption from childhood to adolescence: The Gateshead Millennium Study (2013) (2)
Abstract B124: Selective inhibition of HER2 signaling pathway reveals novel functions of FOXA1 in breast cancer. (2013) (1)
Corrigendum: A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers (2017) (1)
Abstract 1956: High-throughput screens identify microRNAs essential for HER2-positive breast cancer cell growth. (2013) (1)
Short Communication The TP53 Codon 72 Polymorphism May Affect the Function of TP53 Mutations in Breast Carcinomas but not in Colorectal Carcinomas 1 (2002) (1)
Abstract P3-04-03: A seven-gene profile predicting benefit of postmastectomy radiotherapy independently of nodal status in high risk breast cancer (2012) (1)
p16INK4A as a predictive factor in patients with locally advanced breast cancer treated with neoadjuvant doxorubicin monotherapy (2000) (1)
Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors (2013) (1)
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts (2014) (1)
X chromosome inactivation pattern in female patients with breast cancer (2000) (1)
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy (2015) (1)
The impact of the cancer genome project and high-throughput analyses on personalised oncology: today and tomorrow (2012) (1)
Diagnostisk molekylærbiologi ved brystkreft (1998) (1)
Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences (2019) (1)
Abstract P4-11-14: Molecular response in breast cancer treated with neoadjuvant chemotherapy with and without bevacizumab: Results from NeoAva - a randomized phase II study (2012) (1)
Abstract 4742: NOTCH2 in breast cancer: Association of SNP rs11249433 with gene expression in ER-positive breast tumors without p53 gene mutations (2010) (1)
Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status (2014) (1)
331: Integrative analysis reveals extensive association between microRNA expression and mRNA–protein translation (2014) (1)
Corrigendum to “Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer” [Mol. Oncol. 1 (2007) 160–171] (2010) (1)
Genome-wide association study of germline variants and breast cancer-speci fi c mortality (2019) (1)
Cancer Genes: From Mouse to Man (1994) (1)
DNA methylation and gene expression patterns in breast cancer progression from in situ carcinoma to invasive carcinoma (2013) (1)
The multitude of molecular analyses in cancer: the opening of Pandora’s box (2014) (1)
Genetic predisposition to ductal carcinoma in situ of the breast (2016) (1)
794 Allele-specific copy number analysis of breast carcinomas (2010) (1)
Mutations for the people (2010) (1)
Title : Allele-specific disparity in breast cancer (2011) (1)
Running title: Functional proteomics of human breast tumors Title: A novel approach to the study of the functional proteome in breast cancer Running title: Functional proteomics of human breast tumors (2008) (1)
Syddansk Universitet Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12 p 11 locus (2016) (1)
Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study (2014) (1)
TP53mutation is an early event in breast cancer progression. (2009) (1)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
Relation of gene expression-based tumor subclasses to clinical phenotypes (2000) (1)
Familial risk in testicular cancer (1993) (1)
A network analysis to identify mediators of germline-driven differences in breast cancer prognosis (2020) (1)
Expression profiling of breast cancer, influence of tumor genotype and patient genotype (2003) (1)
Contribution of APC and MUTYH mutations to familial adenomatous polyposis susceptibility in Hungary (2015) (1)
Molecular Features of Sub type-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer Graphical (2016) (1)
875 Methylation and mRNA expression profile provide supplementary information about the molecular characteristics of breast cancer tumours with clinical implications (2010) (1)
Individual and combined effects of DNA methylation and copy number alterations on miRNA expression in breast tumors (2013) (1)
Evidence for a sperm mutation resulting in Duchenne muscular dystrophy (1987) (1)
Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium (2015) (1)
Interaction between p53 Staining and High-Dose Chemotherapy in Breast Cancer (2006) (1)
751 Correlation of copy number, gene and protein expression for breast cancer related genes and proteins (2010) (1)
Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3VNTR polymorphisms and gene co-expression (2021) (0)
Genome-wide association study of germline variants and breast cancer-specific mortality (2019) (0)
877 Measuring the level of genomic distortion in breast tumours with increasing histological grade – aprogression model (2010) (0)
Abstract 3128: Immune microenvironment of colorectal tumors and matched liver metastases (2018) (0)
Breast cancer, bone metastasis, non-bone metastasis, copy number imbalances, molecular inversion probe array (2013) (0)
The impact of coding germline variants on contralateral breast cancer risk and survival (2023) (0)
Abstract P4-14-01: A time course study of genomic instability in breast cancer patients receiving neoadjuvant therapy with or without bevacizumab (2013) (0)
P53 POLYMORPHISM AND CERVICAL CANCER. AUTHORS' REPLY (1999) (0)
Altered NDRG1 expression in breast cell lines influences apoptosis (2008) (0)
Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes (2016) (0)
Proteomic Predictors of Outcome After Adjuvant Anti-Hormonal Therapy for Hormone Receptor-Positive Breast Cancer (2012) (0)
Genome-wide association study of germline variants and breast cancer-speci ﬁ c mortality (2019) (0)
Abstract 4850: Paired-end RNA-sequencing based identification of 24 novel fusion genes in breast cancer (2011) (0)
Abstract B59: Age and estrogen-dependent inflammation in breast adenocarcinoma and normal breast tissue (2016) (0)
Genome-Wide DNA Methylation Profiles of Breast Tumors Reveal Loci Associated with Relapse Risk. (2009) (0)
Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry (2016) (0)
Cancer-om-atics: Multilevel interpretation of cancer genome data (2011) (0)
Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing (2016) (0)
460 A Seven-gene Signature Predicting Benefit of Postmastectomy Radiotherapy in High Risk Breast Cancer (2012) (0)
Diet, physical activity and sedentary behaviour in 11–13 year old UK adolescents: The Gateshead Millennium Study (2013) (0)
DNA methylation at enhancers identifies distinct breast cancer lineages (2017) (0)
Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients (2005) (0)
DNA copy number motifs are strong and independent predictors of survival in breast cancer (2020) (0)
[Molecular genetic diagnostics. Technology for detecting mutations in DNA]. (1998) (0)
1096 Molecular signatures of disseminated tumour cells in metastatic breast cancer patients (2009) (0)
Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF (2015) (0)
DNA copy number profiles during tumour progression in breast cancer (2014) (0)
423 Acquisition of Resistance to Anti-Her2 Therapies Promotes a Different Microenvironment Crosstalk Capability (2012) (0)
Haemophilus influenzae infections in siblings: the need for prophylaxis. (1990) (0)
Abstract P6-08-10: Mutational signatures impact the breast cancer transcriptome and distinguish mitotic from immune response pathways (2016) (0)
Breast cancer quantitative proteome and proteogenomic landscape (2019) (0)
Evaluation of metabolomic changes during neoadjuvant chemotherapy combined with bevacizumab in breast cancer using MR spectroscopy (2017) (0)
A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases (2023) (0)
Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas (2015) (0)
cancer clinical treatment response in locally advanced breast Gene expression profiles do not consistently predict the (2011) (0)
No genomic changes in mammographically dense breast (2007) (0)
533 POSTER No genomic changes in mammographically dense breast (2007) (0)
Abstract 1752: Immune-related gene signatures in colorectal liver metastases: Exposing an opportunity for immune modulating therapy (2017) (0)
47 Molecular signatures of long non-coding RNAs in breast cancer patients (2010) (0)
Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors (2019) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
463: A molecular study of breast cancer progression stages from normal breast tissue to invasive cancer (2014) (0)
Abstract B43: Gene expression in breast tissue associated with mammographic density in healthy women (2010) (0)
645 Array comparative genomic hybridization (aCGH) differentiates the major intrinsic subgroups of breast carcinomas (2010) (0)
821 Dissecting the genetic components of gene expression in breast carcinoma (2010) (0)
Development of a blood based breast cancer test for Indian population. (2009) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
Molecular Profiling and Breast Cancer: Towards Better Risk Estimation, Prognostication, and Prediction (2007) (0)
Abstract C47: Inference of tumor evolution during chemotherapy by computational modeling and single cell analysis of diversity. (2013) (0)
Correction to: A systematic comparison of copy number alterations in four types of female cancer (2018) (0)
Paper I WILD TYPE P53 IS EXPRESSED AND PHOSPHORYLATED IN LEUKEMIA CELLS WITH FLT3 Y591 AMPLIFICATION AND BCL-2 OVEREXPRESSION (2006) (0)
Petros Tsipouras 4 (1986) (0)
Fine-mapping identifies two additional susceptibility 9q31.2. (2015) (0)
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (0)
Early breast cancer detection: validation of a commercially available blood-based gene expression test (2010) (0)
338 The HER2 Amplicon Includes Several Genes Required for the Growth and Survival of HER2 Positive Breast Cancer Cells (2012) (0)
Abstract 2842: Dissecting the transcriptional profiles of metastatic and primary disease across cancer types (2017) (0)
Germline SNP analysis as a biomarker for the prediction response to therapy in breast cancer (2008) (0)
Genomics in breast cancer—therapeutic (2005) (0)
831 Applying JISTIC to different stages for breast cancer (2010) (0)
320 Whole genome views on cancer (2003) (0)
Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma (2017) (0)
Abstract DL-1: Molecular Evolution Under Neoadjuvant Chemotherapy (2016) (0)
Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors (2019) (0)
Systems Biology and Genomics of Breast Cancer service (2010) (0)
19 Identification of gene variants and gene expression profiles predicting long term adverse side effects of radiation treatment in breast cancer patients (2009) (0)
367 Genomic profiles of single tumour cells in metastatic breast cancer patients (2010) (0)
Mutation and Polymorphism Report (2001) (0)
A functional SNP in the leader sequence of the manganese superoxide dimutase gene is a predictor of breast cancer patient survival and response to chemotherapy. (2009) (0)
822 Allele-specific aberrations and two dimensional disparity of copy number alterations in breast cancer (2009) (0)
796 Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer (2010) (0)
356 Genetic variation in relation to adverse side-effects of radiotherapy – focus on the metabolism of reactive oxygen species (2010) (0)
Subtype Dependent Alterations of the DNA Methylation Landscape in Breast Cancer. (2009) (0)
[Genetic variation and genetic diseases]. (1989) (0)
Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer (2015) (0)
587 DNA Methylation Profiling Identifies Luminal a Breast Tumors With Poor Survival (2012) (0)
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation (2012) (0)
Abstract 3881: Breast cancer proteogenomics landscape defines subtype specific protein level regulations and reveals proteins coded by pseudogenic loci (2016) (0)
851 Genetic variation in relation to adverse side effects of radiotherapy – focus on the metabolism of reactive oxygen species (2010) (0)
Abstract A72: Next-generation sequencing of disseminated tumor cells (2015) (0)
DNA methylation and gene expression patterns in breast cancer progression from in situ carcinoma to invasive carcinoma (2013) (0)
Functional dissection of the 11q14 amplicon in breast cancer implicates GAB2 as a driver oncogene (2007) (0)
Abstract 4170: MicroRNA-135b influences androgen and estrogen receptor protein levels and regulates proliferation of hormone-receptor positive prostate and breast cancer cells. (2013) (0)
Blood expression profiles as early diagnosis of breast cancer (2008) (0)
Prenatal diagnosis of metachromatic leukodystrophy (MLD) (1974) (0)
Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors (2018) (0)
Breast tumors escape endocrine therapy by ER-independent mechanisms triggered by the coordinated activities of HER2/HER3 and deacetylated FOXA1 (2020) (0)
40 Proffered Paper: Dissecting the Genetic Components of Breast Cancer Transcriptomes (2012) (0)
Common variants in breast cancer risk loci predispose to distinct tumor subtypes (2022) (0)
BUB1 Infrequently Mutated in Human Breast (2003) (0)
Abstract PR06: Lymphocyte invasion of basal breast tumors is associated with wild-type p53 (2015) (0)
Genetic Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility (2003) (0)
Abstract 1083: Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase, ACOX2, in breast cancer (2015) (0)
Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma (2006) (0)
Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCRgenes are associated with breast cancer: a case-control study (2014) (0)
HER-2 activation and TP53 inactivation as predictors of survival in breast cancer (2000) (0)
High density lipoprotein (HDL) polymorphisms in the rabbit, as a model for the study of human serum lipoproteins (1976) (0)
549 Transcriptomics meets metabolomics – correlating snapshots of breast cancer metabolism (2010) (0)
Variation of gene expression profiles in whole blood from a large representative sample of postmenopausal Norwegian women (2008) (0)
404 Genome-wide Association Study in Breast Cancer Survivors Reveals SNPs Associated with Gene Expression of Genes Belonging to MHC Class I and II (2012) (0)
Genetic markers for the prediction of breast density and breast cancer risk (2008) (0)
Abstract LB-051: Tumor heterogeneity and dissemination in breast cancer: Deep sequencing of single disseminated cells from bone marrow compared to primary tumor and lymph node metastases (2015) (0)
Personalized Medicine and Imaging Development and Validation of a Gene Pro fi le Predicting Bene fi t of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer : A Study of Gene Expression in the DBCG 82 bc Cohort (2014) (0)
[Molecular biology. Basis for increased understanding of diseases and improved diagnostics]. (1998) (0)
Abstract 150: Long non-coding RNA are differentially expressed in breast cancer clinical subtypes (2015) (0)
Abstract LB-097: DNA methylation at enhancers distinguishes distinct breast cancer lineages (2017) (0)
Author Correction: Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors (2018) (0)
Abstract LB-337: Systemic shift in genomic aberrations in breast carcinomas during neoadjuvant chemotherapy in combination with bevacizumab (2016) (0)
Abstract P5-10-03: OncomiR-569 deregulate p53 pathway and initiate breast oncogenesis (2012) (0)
Design of a protein signature predicting response to neo-adjuvant treatment with chemotherapy combined with bevacizumab in breast cancer patients. (2019) (0)
Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation (2019) (0)
AD51B in Familial Breast Cancer (2016) (0)
1000 ORAL Luminal A Breast Tumours Divided in Two Clusters by DNA Methylation (2011) (0)
Reply: Increased risk of breast cancer among female relatives of patients with Ataxia-Telangiectasia: a causal relationship? (2005) (0)
Abstract 1123: OncomiR-569 hit p53 pathway and deregulate proliferation of ovarian epithelial cells. (2013) (0)
734 Identification of gene expression alterations associated with fibrosis in breast cancer survivors (2010) (0)
An immunohistochemical panel of antibodies that predicts recurrence in estrogen receptor positive breast cancer patients correlates with the luminal B gene expression subtype (2007) (0)
Structural and Functional Organization of miRNAs (2007) (0)
144 UGT-expression in breast tissue from healthy women is associated with mammographic density (2010) (0)
64: Role of TP53 and other tumour suppressors in breast cancer development and progression (2014) (0)
The NOWAC postgenome cohort: A unique design to develop blood-derived transcriptomic profiles as a mean to biomonitor defined exposure and its effect on cancer incidence (2007) (0)
5202 Deletions of PTEN and FBXW7 in breast carcinomas investigated with array comparative hybridization (aCGH) are associated with reduced survival in a long term follow up clinical cohort (2009) (0)
[Hereditary cancer]. (1998) (0)
Polymorphisms in the cyp19 (aromatase) gene with putative role in the regulation of gene expression (1997) (0)
Mutation screening of the TP53 gene by temporal temperature gel electrophoresis (TTGE). (2014) (0)
[Diagnostic molecular biology in breast cancer]. (1998) (0)
163 A Subtype of Gene Expression with Claudin-low Features in Normal Breast Tissue and in Fibroadenomas (2012) (0)
The MetAction project: Biomarker-directed molecularly matched therapy for end-stage cancer implemented in clinical practice. (2017) (0)
Association of rs12662670 with breast cancer in Asian ER (2012) (0)
[Molecular pathology. A new diagnostic dimension]. (1994) (0)
5169 Comparison and combination of gene-set classifiers for prediction of localized breast cancer survival (2009) (0)
HRDetect : A mutational signature based predictor of BRCA 1 and BRCA 2 deficiency (2017) (0)
833 Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer (2012) (0)
Colorectal tumours examined for genetic changes at chromosomes 13 and 17 with special reference to the RB1 and TP53 genes (1992) (0)
Abstract 3748: p53 status as a determinant of functional duality of estrogen receptor beta in breast cancer: Therapeutic implications (2018) (0)
Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors (2017) (0)
The use of gene technology in the clinical laboratory. (1990) (0)
Letter: Prenatal metachromatic leukodystrophy. (1976) (0)
[Fabry's disease detected by renal biopsy]. (1987) (0)
Denaturing gradient gel electrophoresis: A method for separation of DNA fragments differing by single base-pair substitution (1988) (0)
Cohort Profile: The Gateshead Millennium (2011) (0)
[The 1993 Nobel Prize in chemistry--polymerase chain reaction and directed mutagenesis]. (1993) (0)
Cancer susceptibility genes and common gene variants that increase cancer risk. (2005) (0)
[Gene technology in the prevention of cancer]. (1989) (0)
Loss of chromosome 11p loci during development of male germ cell tumors (1991) (0)
Abstract 2107: Identification of alternative compounds by drug screening of HER2 positive breast cancer cell lines. (2013) (0)
Letter: Serum-H.D.L. in a therosclerotic heart-disease. (1976) (0)
Abstract P6-07-01: A translational and five-year clinical update in patients treated with neoadjuvant chemotherapy randomized to bevacizumab or control in HER2 negative breast cancer (2019) (0)
Abstract P5-05-03: The 5p12 breast cancer susceptibility locus is associated with MRPS30 expression in estrogen receptor - positive tumors (2012) (0)
Mutations in the p53 gene, both within and outside the zinc-binding domains, are associated with increased apoptosis and mitosis in invasive breast carcinomas (1998) (0)
OC-18 The link between the hemostatic system and cancer: A genotypephenotype study in breast cancer patients (2013) (0)
An integrated ‘omics approach highlights the role of epigenetic events to explain and predict response to neoadjuvant chemotherapy and bevacizumab (2022) (0)
Contents, Vol. 65, 1994 (1994) (0)
High density lipoprotein (HDL) polymorphisms in the rabbit, as a model for the study of human serum lipoproteins (1976) (0)
Analysis of inherited and acquired mutations using PCR and denaturing gradient gel electrophoresis (DGGE) (1991) (0)
Relationship between c-erbB-2 and other markers of aggressiveness of gastric carcinoma (1992) (0)
[Gene technology in clinical medicine--technics and tools]. (1989) (0)
TP53 mutations and p53 protein overexpression in human breast carcinomas: Relationship to clinical parameters and survival (1992) (0)
The Wilms' Tumour 1 Gene in Testicular Cancer Patients (1994) (0)
Subject Index Vol. 65, 1994 (1994) (0)
P53 expression/mutation in gastric carcinomas (1992) (0)
Breast cancerPoster presentations (Wed, 23 Sep, 14:00–17:00) Breast cancer – Clinical early diseasePoster5191 Allele-specific aberrations and two dimensional disparity of copy number alterations in breast cancer (2009) (0)
The role of ATM gene in cancer predisposition (1999) (0)
Breast Cancer Prognostication and Risk Prediction in the Post-Genomic Era (2012) (0)
The prognostic value of immune profile in primary and metastastic colorectal cancer – the Oslo-CoMet study (2016) (0)
Abstract B46: Gene expression in colorectal liver metastases: Distinct immune signatures and opportunities for immune modulating therapy (2019) (0)
Employing a blood based gene expression signature to detect early stage breast cancer (2007) (0)
Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway (2016) (0)
Oncogenesis in ovarian cancer (1992) (0)
TP53-mutated breast carcinomas are associated with specific array comparative hybridization (aCGH) patterns involving deletions of 3p, 4p, 4q and 5q (2008) (0)
Distinct Patterns of DNACopy Number Alteration Are Associated with Different Clinicopathological Features and Gene-Expression Subtypes of Breast Cancer (2009) (0)
Copy number motifs expose genome instability type and predict driver events and disease outcome in breast cancer (2019) (0)
Combining data from HR MAS MR spectroscopy and gene expression can refine the subclassification of breast cancer (2008) (0)
A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients (2015) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
[Measurement of gene activity by DNA microarrays]. (2001) (0)
235 speaker THE GENETIC AND EPIGENETIC INFLUENCE ON RADIATION RESPONSE (2011) (0)
Molecular subclassification of breast carcinomas based on aCGH reveals two major groups of tumors with common genomic, transcriptomic and clinicopathological characteristics (2009) (0)
Overrepresentation of transcription factor families in the genesets underlying breast cancer subtypes (2012) (0)
439 Progression of precursor and pre-invasive lesions to invasive cancer (2010) (0)
823 Pathway signatures in breast cancer progression − a genome-scale study based on integration of biology networks, DNA copy number, gene expression and mutations (2010) (0)
Identification of microRNAs regulating HER2 signaling (2011) (0)
5003 ORAL Inhibition of HER2 Positive Breast Cancer Cells by Drug Screening (2011) (0)
A systematic comparison of copy number alterations in four types of female cancer (2016) (0)
Genetic variation in the immunosuppression pathway genes and breast cancer: a pooled analysis of 42,510 cases and 40,577 controls from the Breast (2015) (0)
Abstract P4-07-02: A large integrated-gene profiling analysis identifies prognostic microRNAs and correlated DNA repair genes in estrogen receptor positive and negative breast cancers (2015) (0)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures (2017) (0)
Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry (2023) (0)
5188 A breast cancer fingerprint in peripheral blood–anovel method for early diagnosis (2009) (0)
Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome (2017) (0)
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations (2018) (0)
5087 POSTER An Integrated Approach for Causal Association Among Gene Expression, Genotype Variation and Chronic Fatigue in Breast Cancer (2011) (0)
Commentary Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes (2007) (0)
Abstract A101: The MetAction trial: long-lasting responses to molecularly matched therapy in end-stage cancer (2018) (0)
Abstract 1092: Alterations of the retinoblastoma gene in stage III breast cancers (2010) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
Erratum: Papillomaviruses, p53, and cervical cancer (The Lancet (May 30) (p. 1350)) (1992) (0)
Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway (2016) (0)
Gene expression analysis of formalin-fixed, paraffin-embedded breast cancer tissues using the multiplex branched DNA assay (2008) (0)
195 Gene expression changes in tumours from breast cancer patients receiving radiation therapy (2006) (0)
Abstract PL1-1: Genomic architecture characterizes tumor progression paths and fate in breast cancer patients (2010) (0)
Breast cancer progression – genomic alterations in a continuum of stages (2008) (0)
810 Differential enrichment of pathways in association with TP53 mutation status of breast cancers (2010) (0)
CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers (2021) (0)
Abstract 3049: Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing (2017) (0)
SR2-5: The DNA Copy Number Landscapes and Genomic Architecture; Relevance for Progression and Outcome. (2011) (0)
Abstract P3-10-03: Exploiting p53-dependent functional duality of estrogen receptor-beta to repurpose tamoxifen for triple negative breast cancer therapy (2020) (0)
Molecular subclassification of breast carcinomas based on aCGH, gene expression, IHC and ploidy - relevance for clinical outcome (2008) (0)
Abstract 2781: Gene expression in colorectal liver metastases: Distinct immune signatures and opportunities for immune modulating therapy (2019) (0)
Molecular and Cellular Pathobiology 19 p 13 . 1 Is a Triple-Negative – Speci fi c Breast Cancer Susceptibility Locus (2012) (0)
Letter: Prenatal metachromatic leukodystrophy. (1976) (0)

This paper list is powered by the following services:

Other Resources About Anne-Lise Børresen-Dale

What Schools Are Affiliated With Anne-Lise Børresen-Dale?

Anne-Lise Børresen-Dale is affiliated with the following schools:

University of Oslo